Also, Mirabegron, a β3-AR agonist, as well as Troglitazone, may stimulate UCP1 expression and consequently browning process, although their use shows different limitation in the application for obesity, including a reduced effectiveness and the appearance of side effects [23,24]. This evidence concerns the gene ADRB3 and obesity disorder.